Cargando…
A Systematic Review of High-Dose Methotrexate for Adults with Primary Central Nervous System Lymphoma
SIMPLE SUMMARY: High-dose methotrexate (HDMTX) is the backbone of induction therapy for primary central nervous system lymphoma (PCNSL). There are numerous different protocols to treat PCNSL that incorporate a wide range of HDMTX doses and various combinations with other chemotherapeutic agents. Thi...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10000886/ https://www.ncbi.nlm.nih.gov/pubmed/36900250 http://dx.doi.org/10.3390/cancers15051459 |
_version_ | 1784903994064240640 |
---|---|
author | Villanueva, Gabriela Guscott, Martin Schaiquevich, Paula Sampor, Claudia Combs, Ryan Tentoni, Nicolás Hwang, Miriam Lowe, Jennifer Howard, Scott |
author_facet | Villanueva, Gabriela Guscott, Martin Schaiquevich, Paula Sampor, Claudia Combs, Ryan Tentoni, Nicolás Hwang, Miriam Lowe, Jennifer Howard, Scott |
author_sort | Villanueva, Gabriela |
collection | PubMed |
description | SIMPLE SUMMARY: High-dose methotrexate (HDMTX) is the backbone of induction therapy for primary central nervous system lymphoma (PCNSL). There are numerous different protocols to treat PCNSL that incorporate a wide range of HDMTX doses and various combinations with other chemotherapeutic agents. This systematic review was conducted to summarize the various treatment regimens for PCNSL and determine outcomes among the different doses of HDMTX and combination regimens. The findings are intended to provide guidance on the optimal dose and regimen of HDMTX for the treatment of PCNSL. ABSTRACT: Primary central nervous system lymphoma (PCNSL) is a highly aggressive non-Hodgkin lymphoma that is confined within the CNS. Due to its ability to cross the blood–brain barrier, high-dose methotrexate (HDMTX) is the backbone for induction chemotherapy. This systematic review was conducted to observe outcomes among different HDMTX doses (low, <3 g/m(2); intermediate, 3–4.9 g/m(2); high, ≥5 g/m(2)) and regimens used in the treatment of PCNSL. A PubMed search resulted in 26 articles reporting clinical trials using HDMTX for PCNSL, from which 35 treatment cohorts were identified for analysis. The median dose of HDMTX used for induction was 3.5 g/m(2) (interquartile range IQR, 3–3.5); the intermediate dose was most frequently used in the studies examined (24 cohorts, 69%). Five cohorts used HDMTX monotherapy, 19 cohorts used HDMTX + polychemotherapy, and 11 cohorts used HDMTX + rituximab ± polychemotherapy. Pooled overall response rate (ORR) estimates for low, intermediate, and high dose HDMTX cohorts were 71%, 76%, and 76%, respectively. Pooled 2-year progression-free survival (PFS) estimates for low, intermediate, and high HDMTX dose cohorts were 50%, 51%, and 55%, respectively. Regimens that included rituximab showed a tendency to have higher ORR and 2-year PFS than those that did not include rituximab. These findings indicate that current protocols utilizing 3–4 g/m(2) of HDMTX in combination with rituximab provide therapeutic efficacy in PCNSL. |
format | Online Article Text |
id | pubmed-10000886 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100008862023-03-11 A Systematic Review of High-Dose Methotrexate for Adults with Primary Central Nervous System Lymphoma Villanueva, Gabriela Guscott, Martin Schaiquevich, Paula Sampor, Claudia Combs, Ryan Tentoni, Nicolás Hwang, Miriam Lowe, Jennifer Howard, Scott Cancers (Basel) Systematic Review SIMPLE SUMMARY: High-dose methotrexate (HDMTX) is the backbone of induction therapy for primary central nervous system lymphoma (PCNSL). There are numerous different protocols to treat PCNSL that incorporate a wide range of HDMTX doses and various combinations with other chemotherapeutic agents. This systematic review was conducted to summarize the various treatment regimens for PCNSL and determine outcomes among the different doses of HDMTX and combination regimens. The findings are intended to provide guidance on the optimal dose and regimen of HDMTX for the treatment of PCNSL. ABSTRACT: Primary central nervous system lymphoma (PCNSL) is a highly aggressive non-Hodgkin lymphoma that is confined within the CNS. Due to its ability to cross the blood–brain barrier, high-dose methotrexate (HDMTX) is the backbone for induction chemotherapy. This systematic review was conducted to observe outcomes among different HDMTX doses (low, <3 g/m(2); intermediate, 3–4.9 g/m(2); high, ≥5 g/m(2)) and regimens used in the treatment of PCNSL. A PubMed search resulted in 26 articles reporting clinical trials using HDMTX for PCNSL, from which 35 treatment cohorts were identified for analysis. The median dose of HDMTX used for induction was 3.5 g/m(2) (interquartile range IQR, 3–3.5); the intermediate dose was most frequently used in the studies examined (24 cohorts, 69%). Five cohorts used HDMTX monotherapy, 19 cohorts used HDMTX + polychemotherapy, and 11 cohorts used HDMTX + rituximab ± polychemotherapy. Pooled overall response rate (ORR) estimates for low, intermediate, and high dose HDMTX cohorts were 71%, 76%, and 76%, respectively. Pooled 2-year progression-free survival (PFS) estimates for low, intermediate, and high HDMTX dose cohorts were 50%, 51%, and 55%, respectively. Regimens that included rituximab showed a tendency to have higher ORR and 2-year PFS than those that did not include rituximab. These findings indicate that current protocols utilizing 3–4 g/m(2) of HDMTX in combination with rituximab provide therapeutic efficacy in PCNSL. MDPI 2023-02-25 /pmc/articles/PMC10000886/ /pubmed/36900250 http://dx.doi.org/10.3390/cancers15051459 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Systematic Review Villanueva, Gabriela Guscott, Martin Schaiquevich, Paula Sampor, Claudia Combs, Ryan Tentoni, Nicolás Hwang, Miriam Lowe, Jennifer Howard, Scott A Systematic Review of High-Dose Methotrexate for Adults with Primary Central Nervous System Lymphoma |
title | A Systematic Review of High-Dose Methotrexate for Adults with Primary Central Nervous System Lymphoma |
title_full | A Systematic Review of High-Dose Methotrexate for Adults with Primary Central Nervous System Lymphoma |
title_fullStr | A Systematic Review of High-Dose Methotrexate for Adults with Primary Central Nervous System Lymphoma |
title_full_unstemmed | A Systematic Review of High-Dose Methotrexate for Adults with Primary Central Nervous System Lymphoma |
title_short | A Systematic Review of High-Dose Methotrexate for Adults with Primary Central Nervous System Lymphoma |
title_sort | systematic review of high-dose methotrexate for adults with primary central nervous system lymphoma |
topic | Systematic Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10000886/ https://www.ncbi.nlm.nih.gov/pubmed/36900250 http://dx.doi.org/10.3390/cancers15051459 |
work_keys_str_mv | AT villanuevagabriela asystematicreviewofhighdosemethotrexateforadultswithprimarycentralnervoussystemlymphoma AT guscottmartin asystematicreviewofhighdosemethotrexateforadultswithprimarycentralnervoussystemlymphoma AT schaiquevichpaula asystematicreviewofhighdosemethotrexateforadultswithprimarycentralnervoussystemlymphoma AT samporclaudia asystematicreviewofhighdosemethotrexateforadultswithprimarycentralnervoussystemlymphoma AT combsryan asystematicreviewofhighdosemethotrexateforadultswithprimarycentralnervoussystemlymphoma AT tentoninicolas asystematicreviewofhighdosemethotrexateforadultswithprimarycentralnervoussystemlymphoma AT hwangmiriam asystematicreviewofhighdosemethotrexateforadultswithprimarycentralnervoussystemlymphoma AT lowejennifer asystematicreviewofhighdosemethotrexateforadultswithprimarycentralnervoussystemlymphoma AT howardscott asystematicreviewofhighdosemethotrexateforadultswithprimarycentralnervoussystemlymphoma AT villanuevagabriela systematicreviewofhighdosemethotrexateforadultswithprimarycentralnervoussystemlymphoma AT guscottmartin systematicreviewofhighdosemethotrexateforadultswithprimarycentralnervoussystemlymphoma AT schaiquevichpaula systematicreviewofhighdosemethotrexateforadultswithprimarycentralnervoussystemlymphoma AT samporclaudia systematicreviewofhighdosemethotrexateforadultswithprimarycentralnervoussystemlymphoma AT combsryan systematicreviewofhighdosemethotrexateforadultswithprimarycentralnervoussystemlymphoma AT tentoninicolas systematicreviewofhighdosemethotrexateforadultswithprimarycentralnervoussystemlymphoma AT hwangmiriam systematicreviewofhighdosemethotrexateforadultswithprimarycentralnervoussystemlymphoma AT lowejennifer systematicreviewofhighdosemethotrexateforadultswithprimarycentralnervoussystemlymphoma AT howardscott systematicreviewofhighdosemethotrexateforadultswithprimarycentralnervoussystemlymphoma |